{"id":"doi:10.1016/s2213-8587(24)00182-7","kind":"article","title":"Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","authors":["Barbara M. McGowan","Jens Meldgaard Bruun","Matt Capehorn","Sue D. Pedersen","Kirsi Hannele Pietiläinen","Hanna Angelene","Maria Quiroga","Anette Varbo","David C.W. Lau"],"author_count":9,"year":2024,"published":"2024-07-29","venue":"The Lancet Diabetes & Endocrinology","cited_by":175,"doi":"10.1016/s2213-8587(24)00182-7","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/s2213-8587(24)00182-7","archive_url":"https://space-kitty.com/papers/doi:10.1016/s2213-8587(24)00182-7","updated":null,"pmid":"39089293","pmcid":null,"openalex_id":"W4401067215","pdf_url":null,"abstract":null,"abstract_license":null,"license":null,"is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Diabetes Treatment and Management"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}